The Market Reports

Index

1 PDE 4 Inhibitors Market Overview
1.1 Product Overview and Scope of PDE 4 Inhibitors
1.2 PDE 4 Inhibitors Segment by Type
1.2.1 Global PDE 4 Inhibitors Market Value Comparison by Type (2023-2029)
1.2.2 Rolipram
1.2.3 Tetomilast
1.2.4 Cilomilast
1.2.5 Criborole
1.2.6 Apremilast
1.2.7 Roflumilast
1.2.8 Others
1.3 PDE 4 Inhibitors Segment by Application
1.3.1 Global PDE 4 Inhibitors Market Value by Application: (2023-2029)
1.3.2 Psoriasis
1.3.3 Chronic Obstructive Pulmonary Disease (COPD)
1.3.4 Asthma
1.3.5 Ankylosing Spondylitis (AS)
1.3.6 Inflammatory Bowel Disease (IBD)
1.3.7 Atopic Dermatitis
1.3.8 Rheumatoid Arthritis (RA)
1.3.9 Systemic Lupus Erythematosus (SLE)
1.3.10 Others
1.4 Global PDE 4 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PDE 4 Inhibitors Revenue 2018-2029
1.4.2 Global PDE 4 Inhibitors Sales 2018-2029
1.4.3 Global PDE 4 Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PDE 4 Inhibitors Market Competition by Manufacturers
2.1 Global PDE 4 Inhibitors Sales Market Share by Manufacturers (2018-2023)
2.2 Global PDE 4 Inhibitors Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PDE 4 Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global PDE 4 Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of PDE 4 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PDE 4 Inhibitors, Product Type & Application
2.7 PDE 4 Inhibitors Market Competitive Situation and Trends
2.7.1 PDE 4 Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PDE 4 Inhibitors Players Market Share by Revenue
2.7.3 Global PDE 4 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PDE 4 Inhibitors Retrospective Market Scenario by Region
3.1 Global PDE 4 Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global PDE 4 Inhibitors Global PDE 4 Inhibitors Sales by Region: 2018-2029
3.2.1 Global PDE 4 Inhibitors Sales by Region: 2018-2023
3.2.2 Global PDE 4 Inhibitors Sales by Region: 2024-2029
3.3 Global PDE 4 Inhibitors Global PDE 4 Inhibitors Revenue by Region: 2018-2029
3.3.1 Global PDE 4 Inhibitors Revenue by Region: 2018-2023
3.3.2 Global PDE 4 Inhibitors Revenue by Region: 2024-2029
3.4 North America PDE 4 Inhibitors Market Facts & Figures by Country
3.4.1 North America PDE 4 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America PDE 4 Inhibitors Sales by Country (2018-2029)
3.4.3 North America PDE 4 Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe PDE 4 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PDE 4 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe PDE 4 Inhibitors Sales by Country (2018-2029)
3.5.3 Europe PDE 4 Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PDE 4 Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific PDE 4 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific PDE 4 Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific PDE 4 Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America PDE 4 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PDE 4 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America PDE 4 Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America PDE 4 Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa PDE 4 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PDE 4 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa PDE 4 Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa PDE 4 Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PDE 4 Inhibitors Sales by Type (2018-2029)
4.1.1 Global PDE 4 Inhibitors Sales by Type (2018-2023)
4.1.2 Global PDE 4 Inhibitors Sales by Type (2024-2029)
4.1.3 Global PDE 4 Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global PDE 4 Inhibitors Revenue by Type (2018-2029)
4.2.1 Global PDE 4 Inhibitors Revenue by Type (2018-2023)
4.2.2 Global PDE 4 Inhibitors Revenue by Type (2024-2029)
4.2.3 Global PDE 4 Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global PDE 4 Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global PDE 4 Inhibitors Sales by Application (2018-2029)
5.1.1 Global PDE 4 Inhibitors Sales by Application (2018-2023)
5.1.2 Global PDE 4 Inhibitors Sales by Application (2024-2029)
5.1.3 Global PDE 4 Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global PDE 4 Inhibitors Revenue by Application (2018-2029)
5.2.1 Global PDE 4 Inhibitors Revenue by Application (2018-2023)
5.2.2 Global PDE 4 Inhibitors Revenue by Application (2024-2029)
5.2.3 Global PDE 4 Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global PDE 4 Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer(Anacor)
6.1.1 Pfizer(Anacor) Corporation Information
6.1.2 Pfizer(Anacor) Description and Business Overview
6.1.3 Pfizer(Anacor) PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer(Anacor) PDE 4 Inhibitors Product Portfolio
6.1.5 Pfizer(Anacor) Recent Developments/Updates
6.2 Arcutis Biotherapeutics
6.2.1 Arcutis Biotherapeutics Corporation Information
6.2.2 Arcutis Biotherapeutics Description and Business Overview
6.2.3 Arcutis Biotherapeutics PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Arcutis Biotherapeutics PDE 4 Inhibitors Product Portfolio
6.2.5 Arcutis Biotherapeutics Recent Developments/Updates
6.3 UNION Therapeutics
6.3.1 UNION Therapeutics Corporation Information
6.3.2 UNION Therapeutics Description and Business Overview
6.3.3 UNION Therapeutics PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 UNION Therapeutics PDE 4 Inhibitors Product Portfolio
6.3.5 UNION Therapeutics Recent Developments/Updates
6.4 Innovent Biologics, Inc.
6.4.1 Innovent Biologics, Inc. Corporation Information
6.4.2 Innovent Biologics, Inc. Description and Business Overview
6.4.3 Innovent Biologics, Inc. PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Innovent Biologics, Inc. PDE 4 Inhibitors Product Portfolio
6.4.5 Innovent Biologics, Inc. Recent Developments/Updates
6.5 Amgen
6.5.1 Amgen Corporation Information
6.5.2 Amgen Description and Business Overview
6.5.3 Amgen PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Amgen PDE 4 Inhibitors Product Portfolio
6.5.5 Amgen Recent Developments/Updates
6.6 Ralington pharma LLP
6.6.1 Ralington pharma LLP Corporation Information
6.6.2 Ralington pharma LLP Description and Business Overview
6.6.3 Ralington pharma LLP PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Ralington pharma LLP PDE 4 Inhibitors Product Portfolio
6.6.5 Ralington pharma LLP Recent Developments/Updates
6.7 Beijing Biolab Technology Co., Ltd.
6.6.1 Beijing Biolab Technology Co., Ltd. Corporation Information
6.6.2 Beijing Biolab Technology Co., Ltd. Description and Business Overview
6.6.3 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Product Portfolio
6.7.5 Beijing Biolab Technology Co., Ltd. Recent Developments/Updates
6.8 Nycomed
6.8.1 Nycomed Corporation Information
6.8.2 Nycomed Description and Business Overview
6.8.3 Nycomed PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Nycomed PDE 4 Inhibitors Product Portfolio
6.8.5 Nycomed Recent Developments/Updates
6.9 Forest
6.9.1 Forest Corporation Information
6.9.2 Forest Description and Business Overview
6.9.3 Forest PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Forest PDE 4 Inhibitors Product Portfolio
6.9.5 Forest Recent Developments/Updates
6.10 Bristol Myers
6.10.1 Bristol Myers Corporation Information
6.10.2 Bristol Myers Description and Business Overview
6.10.3 Bristol Myers PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bristol Myers PDE 4 Inhibitors Product Portfolio
6.10.5 Bristol Myers Recent Developments/Updates
6.11 GSK
6.11.1 GSK Corporation Information
6.11.2 GSK PDE 4 Inhibitors Description and Business Overview
6.11.3 GSK PDE 4 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.11.4 GSK PDE 4 Inhibitors Product Portfolio
6.11.5 GSK Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PDE 4 Inhibitors Industry Chain Analysis
7.2 PDE 4 Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PDE 4 Inhibitors Production Mode & Process
7.4 PDE 4 Inhibitors Sales and Marketing
7.4.1 PDE 4 Inhibitors Sales Channels
7.4.2 PDE 4 Inhibitors Distributors
7.5 PDE 4 Inhibitors Customers
8 PDE 4 Inhibitors Market Dynamics
8.1 PDE 4 Inhibitors Industry Trends
8.2 PDE 4 Inhibitors Market Drivers
8.3 PDE 4 Inhibitors Market Challenges
8.4 PDE 4 Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer